Chief Executive Officer
Mr. Oberman brings more than 15 years of international pharmaceutical industry experience to Concordia including his recent role as Chief Executive Officer of specialty pharmaceutical company Sagent Pharmaceuticals, Inc. Sagent was sold to Nichi-Iko Pharmaceutical Co. Ltd., Japan’s largest generic drug manufacturer, in a transaction that closed on August 29, 2016. Prior to Sagent, from November 2012 to December 2014, Mr. Oberman served as President and CEO of Teva Americas Generics, a region which included the U.S., Canada and Latin America. He joined Teva in 2000 and served as President of Teva EMIA (Eastern Europe, Middle East, Israel and Africa), where he led a diverse group of countries in achieving consistent sales growth. Mr. Oberman also served as the Chief Operating Officer of Teva International, and President and CEO of Teva Canada, formerly known as Novopharm Limited.
President & Chief Operating Officer
Prior to joining Concordia, Mr. Kreppner served as Vice-President of Product Development at Trimel Pharmaceuticals Inc. As a co-founder of Trimel, Mr. Kreppner was responsible for all Scientific Operations including R&D, Clinical Development, Manufacturing and Supply Chain. Prior to Trimel, Mr. Kreppner held various senior roles in Operations and Regulatory Affairs with Biovail Pharmaceuticals Inc. from 1997 until 2008, where he most recently served as Vice President, Technology Transfer.
Mr. Kreppner holds a Hons. B.Sc. degree in Biochemistry from the University of Western Ontario, an M.Sc. in Medical Science from McMaster University and an MBA from the Ivey School of Business, University of Western Ontario.
Chief Financial Officer
Mr. Price brings more than 25 years of experience in the healthcare, investment banking and accounting industries to Concordia. Most recently, he served as CFO of Bioventus LLC, a private, equity-backed global provider of medical devices in the orthobiologics field. Prior to his role at Bioventus, Mr. Price was the CFO at EDGAR Online Inc., a financial data, technology and business process outsourcing company. Prior to that, Mr. Price was CFO of Cornerstone Therapeutics, Inc., a publicly traded specialty pharmaceutical company. Mr. Price has previously served as managing director in the healthcare and pharmaceutical services sector at two investment banking firms – Jefferies & Company in New York, and Bear Stearns & Co. in London and New York – and worked at PricewaterhouseCoopers Consulting and Arthur Andersen. He holds an honors degree in Accounting and Financial Management from Lancaster University in the UK and is a member of the Institute of Chartered Accountants in England and Wales.
Chief Legal Officer and Secretary
Mr. Tallarico is Chief Legal Officer and Secretary of Concordia International Corp. Mr. Tallarico manages the Global legal function of the Corporation. Prior to joining the Corporation in 2014, Mr. Tallarico practiced law at Fasken Martineau DuMoulin LLP, an international law firm based out of Toronto, Ontario, with a particular focus on corporate governance, corporate finance and M&A transactions. During his time with the Corporation, Mr. Tallarico has been actively involved and instrumental in various M&A transactions valued at over $4.5 billion. Mr. Tallarico holds a B.A. from the University of Toronto and a J.D. from the University of Windsor.
President of Concordia’s International segment
Mr. Duncan is President of Concordia’s International segment. Mr. Duncan joined Amdipharm Mercury Limited (now Concordia’s International segment) in 2015 as Global Marketing Director and Vice President, Commercial UK and Ireland. He was promoted to Managing Director in 2016 and was responsible for the general management of the segment. Mr. Duncan has worked for 20 years in the life sciences sector within the areas of strategy, sales and marketing, and management. Prior to Concordia, Mr. Duncan held senior management roles in GlaxoWellcome, GlaxoSmithKline, IVAX Pharmaceuticals and Healthcare at Home.